{"id":902202,"date":"2026-05-01T01:36:15","date_gmt":"2026-05-01T01:36:15","guid":{"rendered":"https:\/\/cri-one.com\/?import=902202-valuations-2"},"modified":"2026-06-10T02:34:02","modified_gmt":"2026-06-10T02:34:02","slug":"valuations-part-2-projects-22-40","status":"publish","type":"post","link":"https:\/\/cri-one.com\/blog\/2026\/05\/01\/valuations-part-2-projects-22-40\/","title":{"rendered":"Valuations 2: assessments for projects 22\u201340"},"content":{"rendered":"<p>[lcus_masonry_article]<\/p>\n<p><a href=\"https:\/\/cri-one.com\/store\/all-products\/valuations-2.html\">Valuations 2<\/a> is the assessment companion to <a href=\"https:\/\/cri-one.com\/store\/all-products\/about-2.html\">About the Products 2<\/a>. Both cover <strong>projects 22 through 40<\/strong>. For projects 01\u201321, use <a href=\"https:\/\/cri-one.com\/store\/all-products\/valuations.html\">Valuations<\/a> (Part 1). Figures and narrative on Valuations 2 are provided to help qualified parties compare scope, pricing posture, and market context; they are not a substitute for your own due diligence or professional advice.<\/p>\n<h2>What \u201cvaluation\u201d means on this page<\/h2>\n<p>The page states that valuations are <strong>informational<\/strong>: they summarize stated or negotiated pricing where shown, market-size references where given, competitive positioning language from the catalog, and illustrative revenue scenarios where the page includes them. They do not guarantee liquidity, regulatory clearance, scientific validation beyond what each project section claims, or suitability for any particular balance sheet.<\/p>\n<h2>Qualified buyers: proposals and data rooms<\/h2>\n<p>Valuations 2 describes a practical path for serious interest: structured terms for portfolio or single-project acquisition, tailored proposals, and optional technical data room access for diligence. Portfolio pricing is described as dependent on scope and use. Treat those paragraphs as process guidance; execution is always subject to verification and a written agreement.<\/p>\n<h2>Reading the table of contents<\/h2>\n<p>The on-page table of contents lists each project from 22 to 40 with a short price or \u201cnegotiated\u201d label. The body sections expand factors such as intellectual property posture (including pending applications where cited), market comparisons where provided, and revenue illustrations where the page models them. When a section includes health-related research, the source page carries explicit limitations (for example that certain lines are research discoveries, not proven human cures, and are not FDA-approved as drugs). Any blog summary should preserve that distinction; do not shorten it in a way that implies clinical proof where the store page does not.<\/p>\n<h2>Contact consistency<\/h2>\n<p>Before publishing calls to action, align the article with the site\u2019s current <strong>preferred contact policy<\/strong> as shown in the store footer (email and postal mail). If the Valuations page and the footer ever differ on phone versus mail-only preferences, follow the footer or update the page so visitors see one consistent instruction.<\/p>\n<h2>Cross-links<\/h2>\n<ul>\n<li><a href=\"https:\/\/cri-one.com\/store\/all-products\/about-2.html\">About the Products 2<\/a> \u2014 package contents and handoff descriptions.<\/li>\n<li><a href=\"https:\/\/cri-one.com\/store\/all-products\/valuations-2.html\">Valuations 2<\/a> \u2014 this assessment set.<\/li>\n<li><a href=\"https:\/\/cri-one.com\/store\/all-products\/valuations.html\">Valuations<\/a> \u2014 Part 1 (projects 01\u201321).<\/li>\n<\/ul>\n<p>[\/lcus_masonry_article]<\/p>\n<p><!-- crione-related-start --><\/p>\n<div class=\"crione-rel\">\n<style>.crione-rel{margin:2em 0;padding:1.25em 0;border-top:2px solid #ddd;border-bottom:2px solid #ddd;}.crione-rel-title{font-weight:600;font-size:1.05em;margin-bottom:.75em;}.crione-rel-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(180px,1fr));gap:1em;}.crione-rel-card{display:block;text-decoration:none;color:inherit;border:1px solid #e5e5e5;border-radius:6px;padding:.75em;transition:box-shadow .15s;}.crione-rel-card:hover{box-shadow:0 4px 12px rgba(0,0,0,.08);}.crione-rel-card img{display:none;}.crione-rel-name{font-weight:500;line-height:1.3;margin-bottom:.25em;}.crione-rel-price{font-weight:600;color:#0a7;}<\/style>\n<div class=\"crione-rel-title\">Related from cri-one.com\/store<\/div>\n<div class=\"crione-rel-grid\"><a class=\"crione-rel-card\" href=\"https:\/\/cri-one.com\/store\/metallodrugdb-complete-database-acquisition-300-compounds.html\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/cri-one.com\/store\/pub\/media\/catalog\/product\/m\/e\/metallodrugdb-full-sale.png\" alt=\"MetalloDrugDB - Complete Database Acquisition (300 Compounds)\" loading=\"lazy\"><\/p>\n<div class=\"crione-rel-name\">MetalloDrugDB &#8211; Complete Database Acquisition (300 Compounds)<\/div>\n<div class=\"crione-rel-price\">$40000000.00<\/div>\n<p><\/a><a class=\"crione-rel-card\" href=\"\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/cri-one.com\/store\/pub\/media\/catalog\/product\/e\/j\/ej-pof-010.png\" alt=\"Electric Jet - Proof of Function 10: Market Opportunity\" loading=\"lazy\"><\/p>\n<div class=\"crione-rel-name\">Electric Jet &#8211; Proof of Function 10: Market Opportunity<\/div>\n<div class=\"crione-rel-price\">$1.69<\/div>\n<p><\/a><a class=\"crione-rel-card\" href=\"https:\/\/cri-one.com\/store\/autophi-v18-achievement-ic-collection.html\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/cri-one.com\/store\/pub\/media\/catalog\/product\/i\/c\/ic-v18-achievement.png\" alt=\"AutoPhi V18-Achievement IC Collection\" loading=\"lazy\"><\/p>\n<div class=\"crione-rel-name\">AutoPhi V18-Achievement IC Collection<\/div>\n<div class=\"crione-rel-price\">$9090000000000.00<\/div>\n<p><\/a><\/div>\n<\/div>\n<p><!-- crione-related-end --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>How to use Valuations 2 with About the Products 2: informational assessments, buyer process, diligence, and links to Part 1.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[537],"tags":[],"class_list":["post-902202","post","type-post","status-publish","format-standard","hentry","category-products"],"_links":{"self":[{"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/posts\/902202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/comments?post=902202"}],"version-history":[{"count":4,"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/posts\/902202\/revisions"}],"predecessor-version":[{"id":903284,"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/posts\/902202\/revisions\/903284"}],"wp:attachment":[{"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/media?parent=902202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/categories?post=902202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cri-one.com\/blog\/wp-json\/wp\/v2\/tags?post=902202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}